75 completed, 20 terminated, 8 unknown, 5 withdrawn. 119 Phase 2, 40 Phase 1, 2 Phase 3.
Follow Acute Myelogenous Leukemia: new trials by email Literature Review of Acute Myelogenous Leukemia trials Research Report on Acute Myelogenous Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT AdaptNK, Fludarabine, Cyclophosphamide - Relapsed Adult AML, Refractory AML | Phase 1 / Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 18 | 2026-05-08 | 2026-05-19 |
| Cord Blood Transplantation in Children and Young Adults With Blood Cancer Cord Blood Units, Total Body Irradiation, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2026-04-28 | 2026-05-14 |
| ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Cyclophosphamide, Fludarabine, Thiotepa - Acute Myelogenous Leukemia, Acute Lymphatic Leukemia | Phase 2 | Suspended | Leland Metheny | 20 | 2026-04-08 | 2026-09-10 |
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML 131I-apamistamab, Fludarabine, Cyclophosphamide - Acute Leukemia, Myeloid Leukemia | Phase 2 / Phase 3 | Not yet recruiting | Actinium Pharmaceuticals | 306 | 2026-01-01 | 2025-09-10 |
| Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood Haplo-Identical / Cord Blood Transplant - aGVHD, Acute Myelogenous Leukemia | Phase 2 | Recruiting | Case Comprehensive Cancer Center | 36 | 2025-08-13 | 2026-09-15 |
| Allo HSCT Using RIC and PTCy for Hematological Diseases Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 56 | 2023-05-01 | 2026-07-06 |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Busulfan, Fludarabine, Total-body irradiation - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 2 | Active not recruiting | Center for International Blood and Marrow Transplant Research | 300 | 2021-09-30 | 2026-03-18 |
| MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies MGTA-145, Plerixafor - Related Donors Donating PBSC to a Family Member, Healthy Donors | Phase 2 | Terminated | Ensoma | 7 | 2021-06-16 | 2024-11-06 |
| Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Emavusertib, Venetoclax - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Suspended | Curis, Inc. | 366 | 2020-07-06 | 2026-03-19 |
| Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia CD33CART autologous, CD33CART allogeneic - Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Active not recruiting | Center for International Blood and Marrow Transplant Research | 52 | 2020-01-08 | 2025-07-14 |
| GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies GTB-3550 TriKE® Phase I, GTB-3550 TriKE® Phase II - High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | GT Biopharma, Inc. | 12 | 2020-01-01 | 2022-11-10 |
| Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers galinpepimut-S, pembrolizumab, Montanide - Acute Myelogenous Leukemia, Ovarian Cancer | Phase 1 / Phase 2 | Completed | Sellas Life Sciences Group | 26 | 2019-09-30 | 2024-11-19 |
| Bisantrene for Relapsed /Refractory AML Bisantrene - Acute Myelogenous Leukemia, Allogeneic Stem Cell Transplantation | Phase 2 | Completed | Sheba Medical Center | 10 | 2019-07-18 | 2020-08-07 |
| A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS Nerofe, Doxorubicin - Acute Myelogenous Leukemia, Myelodysplastic Syndromes | Phase 2 | Withdrawn | Immune System Key Ltd | 2018-10-25 | 2020-07-31 | |
| DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission DC/AML Fusion Vaccine, Observation - Acute Myelogenous Leukemia | Phase 2 | Active not recruiting | Beth Israel Deaconess Medical Center | 82 | 2017-06-01 | 2026-09-29 |
| Allo HSCT Using RIC for Hematological Diseases Allopurinol, Fludarabine, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 156 | 2017-03-09 | 2023-09-21 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies Infusion of Treg - Acute Lymphoblastic Leukemia, Burkitt Lymphoma | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 3 | 2017-02-16 | 2020-09-29 |
| Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101) Ciprofloxacin 750 MG, Etoposide, Ciprofloxacin 1000 MG - Leukemia, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | University of Florida | 11 | 2016-12-16 | 2022-08-05 |
| CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML anti-CD33 CAR-NK cells - Acute Myelogenous Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-10-01 | 2016-12-06 |
| Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy Inecalcitol, Placebo Oral Tablet - Acute Myelogenous Leukemia | Phase 2 | Unknown | Hybrigenics Corporation | 110 | 2016-06-01 | 2017-07-02 |
Showing 20 of 119. Sign in to see all of them.
Leukemia, Myeloid, Acute (119) · Myelodysplastic Syndromes (58) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (39) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (28) · Leukemia (24) · Hodgkin Disease (17) · Lymphoma, Non-Hodgkin (17) · Leukemia, Lymphocytic, Chronic, B-Cell (15) · Multiple Myeloma (13) · Lymphoma (12) · Recurrence (7) · Myeloproliferative Disorders (6) · Primary Myelofibrosis (6) · Anemia, Aplastic (5) · Hematologic Diseases (5)
Hemic and Lymphatic Diseases (119) · Neoplasms by Histologic Type (118) · Neoplasms (117) · Hematologic Diseases (114) · Leukemia, Myeloid (114) · Leukemia (95) · Bone Marrow Diseases (63) · Immune System Diseases (42) · Immunoproliferative Disorders (41) · Lymphatic Diseases (41) · Leukemia, Lymphoid (39) · Lymphoproliferative Disorders (39) · Pathological Conditions, Signs and Symptoms (37) · Disease Attributes (36) · Pathologic Processes (36)
fludarabine (21) · Cyclophosphamide (17) · Whole-Body Irradiation (14) · Cytarabine (13) · Clofarabine (12) · fludarabine phosphate (12) · Busulfan (10) · Tacrolimus (10) · Azacitidine (8) · Melphalan (8) · Mycophenolic Acid (8) · Interleukin-2 (7) · Decitabine (6) · Gemtuzumab (6) · Cyclosporine (5)
M.D. Anderson Cancer Center (15) · Masonic Cancer Center, University of Minnesota (8) · Genzyme, a Sanofi Company (4) · New York Medical College (4) · Center for International Blood and Marrow Transplant Research (3) · Dana-Farber Cancer Institute (3) · AbbVie (2) · Asan Medical Center (2) · Baylor College of Medicine (2) · Beth Israel Deaconess Medical Center (2) · Eleos, Inc. (2) · Memorial Sloan Kettering Cancer Center (2) · Millennium Pharmaceuticals, Inc. (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · University of Bergen (2)
United States (97) · France (6) · Germany (5) · Italy (5) · South Korea (4) · Spain (4) · Australia (3) · Belgium (3) · Canada (3) · Israel (3) · Norway (2) · United Kingdom (2) · China (1) · Czechia (1) · Japan (1)
Guillermo Garcia-Manero, MD (2) · Jacalyn Rosenblatt, MD (2) · Jorge Cortes, MD (2) · Jorge E Cortes, MD (2) · Leland Metheny, MD (2) · Oystein Bruserud, MD (2) · Richard M. Stone, MD (2) · Steven Devine, MD (2) · Abby R Rosenberg, MD, MS (1) · Akhil Baranwal, MD (1) · Amir A Toor, MD (1) · Andrew Artz, MD (1) · Andromachi Scaradavou, MD (1)
PMID 28877686, PMID 33917201, PMID 17596541, PMID 18922099, PMID 19007987, PMID 19556425, PMID 19667400, PMID 20026805, PMID 21967976, PMID 22133778, PMID 22829110, PMID 23065508, PMID 23524640, PMID 23710698, PMID 23813900, PMID 24081577, PMID 24573552, PMID 25682597, PMID 27520294, PMID 27931243, PMID 28054442, PMID 28939558, PMID 29097499, PMID 29248669, PMID 29674506, PMID 29705733, PMID 30890544, PMID 31037789, PMID 31092732, PMID 31266741, PMID 31551349, PMID 31680625, PMID 33394722, PMID 33960833, PMID 34152898, PMID 34531250, PMID 34817581, PMID 34839054, PMID 35829925, PMID 36226495, PMID 36230640, PMID 36370742, PMID 36724515, PMID 36932165, PMID 38091578, PMID 38841781, PMID 39670843, PMID 39792934, PMID 39819505, PMID 39921387
2008 (3), 2014 (1), R01HL114591 (1)